Abstract
Despite the ever-progressing technological advances in producing data in health and clinical research, the generation of new knowledge for medical benefits through advanced analytics still lags behind its full potential. Reasons for this obstacle are the inherent heterogeneity of data sources and the lack of broadly accepted standards. Further hurdles are associated with legal and ethical issues surrounding the use of personal/patient data across disciplines and borders. Consequently, there is a need for broadly applicable standards compliant with legal and ethical regulations that allow interpretation of heterogeneous health data through in silico methodologies to advance personalized medicine. To tackle these standardization challenges, the Horizon2020 Coordinating and Support Action EU-STANDS4PM initiated an EU-wide mapping process to evaluate strategies for data integration and data-driven in silico modelling approaches to develop standards, recommendations and guidelines for personalized medicine. A first step towards this goal is a broad stakeholder consultation process initiated by an EU-STANDS4PM workshop at the annual COMBINE meeting (COMBINE 2019 workshop report in same issue). This forum analysed the status quo of data and model standards and reflected on possibilities as well as challenges for cross-domain data integration to facilitate in silico modelling approaches for personalized medicine.
Highlights
A key strategic objective of EU-STANDS4PM is to engage with relevant stakeholders
EU-STANDS4PM consulted the COMBINE (Computational Modelling in Biology Network) community to address crucial requirements with respect to the development of data and model standards as well as data integration tasks in research and clinic, including ethical and legal aspects. These areas were discussed at the annual meeting of COMBINE in moderated round table workshops covering six central topics presented below and that conclude in a first set of recommendations to key actors
A key output of the discussed workshop topics was a summary of challenges associated with the implementation of data-driven in silico methodologies in personalized medicine and clinical practice
Summary
A key strategic objective of EU-STANDS4PM is to engage with relevant stakeholders. Through specific awareness actions, including workshops, the project provides a forum to assess strategies for health data integration (such as genetic, expression, proteomics, demographic, clinical, and lifestyle exposures) as well as. This proactive networking process is central to the major deliverable of EU-STANDS4PM, which is to jointly develop universal standards as well as guidelines and recommendations for in silico methodologies relevant for personalized medicine in a concerted action To initiate this process, EU-STANDS4PM consulted the COMBINE (Computational Modelling in Biology Network) community to address crucial requirements with respect to the development of data and model standards as well as data integration tasks in research and clinic, including ethical and legal aspects. EU-STANDS4PM consulted the COMBINE (Computational Modelling in Biology Network) community to address crucial requirements with respect to the development of data and model standards as well as data integration tasks in research and clinic, including ethical and legal aspects These areas were discussed at the annual meeting of COMBINE in moderated round table workshops covering six central topics presented below and that conclude in a first set of recommendations to key actors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.